ENT/Head and Neck Cancers

219885 GALAXIES H&N-202

A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Open at Paris since : 27/02/2024
Target : Adult
Phase : Phase II

Trial description

It increases the ability of new immunotherapy combinations to prevent or increase tumor progression (anti-tumor activity) by reporting CETEC participant cancer clearance with recurrent/metastatistic PD-L1 positivity.

Url of the trial

Main investigator

CHRISTOPHE LE TOURNEAU

Professeur - Médecin

Contact